Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Ferrer
Elena
E
Niubo
Jordi
J
Crespo
Manel
M
Gatell
Josep Maria
JM
Sanz
Jose
J
Veloso
Sergio
S
Llibre
Josep Maria
JM
Barrufet
Pilar
P
Sanchez
Pochita
P
Podzamczer
Daniel
D
D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000494:pharmacology* / Q000627:therapeutic use; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D019259:Lamivudine / Q000494:pharmacology* / Q000627:therapeutic use; D009154:Mutation; D013030:Spain; D013045:Species Specificity; D017211:Treatment Failure; D019562:Viral Load; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D019259:Lamivudine; D000099227:Abacavir; C098320:efavirenz